Diethylamine

Diethylamine

SCHEMBL3973793

CCNCC.Cc1cccn1C

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CCKAR

The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.39
TRIM33 Q9UPN9 1/20 0.39
ALDH1A1 P00352 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
MAPT P10636 1/20 0.34
POLB P06746 1/20 0.33
TAAR1 Q96RJ0 2/20 0.33
CYP2C9 P11712 1/20 0.33
KDM4E B2RXH2 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
LMNA P02545 1/20 0.32
INMT O95050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143814 0.83
Dimethylamine SCHEMBL385867 0.81 TSHR (0.39) TRIM24TRIM33ALDH1A1CYP3A4CYP2D6
Ammonia Solution, Strong SCHEMBL27847806 0.81
Fluoride SCHEMBL30212653 0.81
SCHEMBL8676817 0.81
SCHEMBL4282205 0.81
Formamide SCHEMBL4997873 0.76 TRIM24 (0.50) TRIM24TRIM33ALDH1A1TSHRMEN1
Ethoxycarbonyl Group SCHEMBL28063745 0.75 TRIM24 (0.41) TRIM24TRIM33ALDH1A1TSHRPOLB
SCHEMBL29251687 0.74 CYP2C9 (0.46) TRIM24TRIM33ALDH1A1CYP2C19TSHR
SCHEMBL1038510 0.72 ALDH1A1 (0.57) ALDH1A1CYP3A4CYP2D6CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547790-B2 Optically active 4,4-di-substituted oxazolidine derivative and method for producing same SANKYO COMPANY, LIMITED (JP) 2009-06-16 US disclosed
US-20080108828-A1 Optically Active 4,4-Di-Substituted Oxazolidine Derivative and Method for Producing Same SANKYO COMPANY, LIMITED (JP) 2008-05-08 US disclosed
EP-1806344-A1 OPTICALLY ACTIVE 4,4-DISUBSTITUTED OXAZOLIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME Sankyo Company, Limited (JP) 2007-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108828-A1 Optically Active 4,4-Di-Substituted Oxazolidine Derivative and Method for Producing Same CBR3, C9, COX6C TRIM24 4750/4885TRIM33 4853/4885ALDH1A1 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.